Neoadjuvant giredestrant plus palbociclib (P) vs. anastrozole (A) plus P in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+, HER2-eBC): Patient (pt)-reported outcomes (PROs) in the randomized, open-label, international phase II coopERA BC study

被引：0
|
作者：
Park, Yeon Hee
Quiroga, Vanesa
Fasching, Peter A.
Bardia, Aditya
Lopez-Valverde, Vanesa
Crnjevic, Tanja Badovinac
Steinseifer, Jutta
Devine, Jacob
Hurvitz, Sara A.
机构：
[1] Samsung Med Ctr, Seoul, South Korea
[2] GEICAM Spanish Breast Canc Grp, Madrid, Spain
[3] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Comprehens Canc Ctr CCC Erlangen EMN, Erlangen, Germany
[4] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA
[5] F Hoffmann La Roche Ltd, Basel, Switzerland
[6] Genentech Inc, South San Francisco, CA USA
[7] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
591
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Neoadjuvant Chemotherapy with Concurrent Letrozole for Estrogen Receptor-Positive and HER2-Negative Breast Cancer: An Open-Label, Single-Center, Nonrandomized Phase II Study (NeoCHAI)
    Chae, Heejung
    Sim, Sung Hoon
    Kwon, Youngmi
    Lee, Eun-Gyeong
    Han, Jai Hong
    Jung, So-Youn
    Lee, Seeyoun
    Kang, Han-Sung
    Kim, Yeon-Joo
    Kim, Tae Hyun
    Lee, Keun Seok
    CANCERS, 2024, 16 (18)
  • [22] Neoadjuvant nivolumab (NIVO) plus palbociclib (PALBO) plus anastrozole (ANA) for estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer (BC): CheckMate 7A8
    Jerusalem, G.
    Prat, A.
    Salgado, R. F.
    Reinisch, M.
    Saura, C.
    Ruiz Borrego, M.
    Nikolinakos, P.
    Filian, J.
    Ades, F.
    Huang, N.
    Mazzei-Abba, A.
    Tolaney, S. M.
    ANNALS OF ONCOLOGY, 2022, 33 : S165 - S166
  • [23] SOLTI-1802 ONAWA trial: A window of opportunity trial of onapristone (ONA) in postmenopausal women with estrogen and progesterone receptor-positive/HER2-negative (ER+/PgR+/HER2-) early breast cancer (EBC)
    Bellet, M.
    Morales Murillo, S.
    Gasol Cudos, A.
    Amillano, K.
    Chic, N.
    Gonzalez-Farre, X.
    Villagrasa, P.
    Ferrero-Cafiero, J. M.
    Pascual, T.
    Prat, A.
    Lange, C.
    Saura Manich, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S36 - S36
  • [24] Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial
    Prat, Aleix
    Saura, Cristina
    Pascual, Tomas
    Hernando, Cristina
    Munoz, Montserrat
    Pare, Laia
    Gonzalez Farre, Blanca
    Fernandez, Pedro L.
    Galvan, Patricia
    Chic, Nuria
    Gonzalez Farre, Xavier
    Oliveira, Mafalda
    Gil-Gil, Miguel
    Arumi, Miriam
    Ferrer, Neus
    Montano, Alvaro
    Izarzugaza, Yann
    Llombart-Cussac, Antonio
    Bratos, Raquel
    Gonzalez Santiago, Santiago
    Martinez, Eduardo
    Hoyos, Sergio
    Rojas, Beatriz
    Antonio Virizuela, Juan
    Ortega, Vanesa
    Lopez, Rafael
    Celiz, Pamela
    Ciruelos, Eva
    Villagrasa, Patricia
    Gavila, Joaquin
    LANCET ONCOLOGY, 2020, 21 (01): : 33 - 43
  • [25] Primary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC)
    Saura, C.
    de Azambuja, E.
    Hlauschek, D.
    Oliveira, M.
    Zardavas, D.
    Jallitsch-Halper, A.
    de la Pena, L.
    Nuciforo, P.
    Ballestrero, A.
    Fornier, M. N.
    Boer, K.
    Ciruelos, E.
    Valero, V.
    Wilson, T. R.
    Stout, T. J.
    Hsu, J. Y.
    Shi, Y.
    Piccart, M.
    Gnant, M.
    Baselga, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in women and men with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC)
    Rugo, Hope S.
    Bardia, Aditya
    Cortes, Javier
    Curigliano, Giuseppe
    Hamilton, Erika
    Hurvitz, Sara A.
    Loibl, Sibylle
    Kummel, Sherko
    Scartoni, Simona
    Matheny, Shannon
    Theall, Kathy Puyana
    O'shaughnessy, Joyce
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 32 - 32
  • [27] Elacestrant combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC): Preliminary data from ELEVATE, a phase Ib/II, open-label, umbrella study
    Rugo, H. S.
    O'Shaughnessy, J.
    Cortes, J.
    Bardia, A.
    Hamilton, E. P.
    Hurvitz, S. A.
    Kaklamani, V.
    Mchayleh, W.
    Romero, P. Munoz
    Vallespir, B. Piza
    Wasserman, T.
    Theall, K. P.
    Tolaney, S. M.
    ANNALS OF ONCOLOGY, 2024, 35 : S372 - S373
  • [28] Phase II randomized trial of neoadjuvant trastuzumab and pertuzumab (TP) with either palbociclib plus letrozole (Pal plus L) or paclitaxel (Pac) for elderly patients with estrogen receptor & HER2 positive (ER+/HER2+) breast cancer (BC) (International Breast Cancer Study Group IBCSG 55-17, TOUCH)
    Biganzoli, L.
    Brain, E.
    Malorni, L.
    Risi, E.
    Regan, M. M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [29] ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or Ill estrogen receptor-positive HER2-negative breast cancer (ER+HER2-BC) in postmenopausal (PM) women: Alliance A011106.
    Ma, Cynthia X.
    Suman, Vera J.
    Leitch, A. Marilyn
    Sanati, Souzan
    Vij, Kiran R.
    Unzeitig, Gary Walter
    Hoog, Jeremy
    Watson, Mark
    Hahn, Olwen Mary
    Guenther, J. Michael
    Caudle, Abigail Suzanne
    Dockter, Travis
    Korde, Larissa A.
    Weiss, Anna
    Hunt, Kelly
    Hudis, Clifford A.
    Winer, Eric P.
    Partridge, Ann H.
    Carey, Lisa A.
    Ellis, Matthew James
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [30] Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) operable breast cancer (BC).
    Moore, Heather M.
    Boni, Valentina
    Bellet, Meritxell
    De Las Heras, Begona Bermejo
    Cortes, Maria Gion
    Oakman, Catherine
    Schmid, Peter
    Trinh, Xuan Bich
    Wheatley, Duncan
    Jhaveri, Komal L.
    Kabos, Peter
    Lim, Elgene
    Velu, Thierry
    Metcalfe, Ciara
    Gates, Mary R.
    Chang, Ching-Wei
    Bond, John
    Goldstein, Leonard D.
    Lauchle, Jennifer O'Hara
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345